Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Award vesting grace period (in years) Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Grace Period Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Grace Period Trading Arrangement: Trading Arrangement [Axis] Schedule of Other Long-Term Assets Schedule of Other Assets, Noncurrent [Table Text Block] Maximum Maximum [Member] Statistical Measurement Statistical Measurement [Domain] Underwriters allotment option, term (in days) Sale Of Sock, Over-Allotment Option, Term Sale Of Sock, Over-Allotment Option, Term Title of 12(b) Security Title of 12(b) Security Document Fiscal Year Focus Document Fiscal Year Focus Line of credit, maximum borrowing capacity, number of available tranches Line Of Credit Facility, Maximum Borrowing Capacity, Number Of Available Tranches Line Of Credit Facility, Maximum Borrowing Capacity, Number Of Available Tranches Dilutive effect of common stock options and SARs Common Stock Options and Stock Appreciation Rights (SARS) [Member] Common Stock Options and Stock Appreciation Rights (SARS) Balance at Beginning of Period Balance at End of Period Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance Adjustment to Compensation, Amount Adjustment to Compensation Amount Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Segment Reporting [Abstract] Refund liability to customer, gross Contract with Customer, Refund Liability, Gross Contract with Customer, Refund Liability, Gross Schedule of Assets Measured or Disclosed at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Common stock $0.00001 par value; 500,000,000 and 350,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 271,742,717 and 265,424,818 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively Common Stock, Value, Issued 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Compensation and related benefits Employee-related Liabilities, Current Other Other Assets, Miscellaneous, Noncurrent Upfront payment Asset Acquisition, Upfront Payment Asset Acquisition, Upfront Payment Line of Credit Line of Credit [Member] Restatement Determination Date Restatement Determination Date Contract asset Contract with Customer, Asset, after Allowance for Credit Loss Write-down of inventory Inventory Write-down Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service [Member] Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service Restricted stock unit vesting (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Minimum purchase commitment Purchase Commitment, Remaining Minimum Amount Committed Term Loan Facility, Tranche B Term Loan Facility, Tranche B [Member] Term Loan Facility, Tranche B Additions Contract With Customer Liability Additions Contract with customer liability additions. Warrant to purchase common stock (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Allowance for credit loss Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Contract with Customer, Basis of Pricing Contract with Customer, Basis of Pricing [Domain] Amendment Flag Amendment Flag Current liabilities: Liabilities, Current [Abstract] Provision for bad debts Accounts Receivable, Credit Loss Expense (Reversal) Inventory [Axis] Inventory [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Contract liability: Contract Liability [Roll Forward] Contract Liability Inventories, long-term Long-term inventories Inventory, Noncurrent Change in fair value of warrant liability Change in fair value of warrant liability Fair Value Adjustment of Warrants Leases [Abstract] Maximum number of shares per employee in any offering period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Entity Address, State or Province Entity Address, State or Province Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Asset Acquisition [Axis] Asset Acquisition [Axis] Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Royalty payments Royalty Payments Due Royalty payments due. Basic (in shares) Denominator for basic net income (loss) per share - weighted average outstanding shares of common stock (in shares) Weighted Average Number of Shares Outstanding, Basic Share Based Compensation Award Tranche One Share-Based Payment Arrangement, Tranche One [Member] Balance at Beginning of Period Balance at End of Period Contract asset Contract with Customer, Asset, after Allowance for Credit Loss, Current Goodwill, accumulated impairment losses Goodwill, Impaired, Accumulated Impairment Loss Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount SEC Schedule, 12-09, Valuation Allowances and Reserves Type SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Work-in-process Inventory, Work in Process, Net of Reserves Termination of agreement eligible by counterparty, period after effective agreement date (in months) Contract With Customer, Termination Notice Period, Period After Effective Agreement Date Contract With Customer, Termination Notice Period, Period After Effective Agreement Date SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Entity Address, City or Town Entity Address, City or Town Upfront payments Asset Acquisition, Consideration Transferred Lessee, operating lease, leased square feet Lessee, Operating Lease, Leased Square Feet Lessee, Operating Lease, Leased Square Feet Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Title of Individual Title and Position [Domain] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Product revenue, net Product [Member] Panion royalty Royalty Expense Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Payments for royalties Payments for Royalties License And Other Revenue License And Other Revenue [Member] License And Other Revenue Proceeds from issuance of stock under employee stock purchase plan Proceeds from Stock Plans Tiered royalties (as percent) Revenue, Remaining Performance Obligation, Variable Consideration, Royalty Percentage Revenue, Remaining Performance Obligation, Variable Consideration, Royalty Percentage Level 2 Fair Value, Inputs, Level 2 [Member] Other income (expense) Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Line of credit, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Current portion of long-term debt Long-Term Debt, Current Maturities License License [Member] Non-cash operating lease expense Straight Line Rent Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Employees Employees [Member] Employees Cyclerion Cyclerion [Member] Cyclerion New Accounting Pronouncements - Recently Adopted/Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Property and equipment included in accounts payable Capital Expenditures Incurred but Not yet Paid Deferred revenue Increase (Decrease) in Contract with Customer, Liability Schedule of Segment Financial Information Segment Reporting [Table Text Block] Gain on the sale of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Use of Estimates Use of Estimates, Policy [Policy Text Block] Termination period, prior written notice (in days) Termination Period, Prior Written Notice Termination Period, Prior Written Notice Schedule of Components of Accrued Expenses and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Total term loans Long-Term Debt Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Schedule of Future Commitments under Non-Cancelable Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Supplemental disclosures of non-cash financing and investing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] SEC Schedule, 12-09, Valuation Allowances and Reserves SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Percentage of net product margin on sales in collaborative arrangement Collaborative Arrangement, Rights And Obligations, Percentage Of Net Product Margin On Sales Collaborative Arrangement, Rights And Obligations, Percentage Of Net Product Margin On Sales Non-cash royalty revenue related to sale of future royalties Contractual Arrangement, Royalties Agreement, Noncash Royalty Revenue Contractual Arrangement, Royalties Agreement, Noncash Royalty Revenue Preferred stock, outstanding (in shares) Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two CAPITAL STOCK Equity [Text Block] Less: Costs and Expenses [Abstract] Security Exchange Name Security Exchange Name Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Development milestone payment Asset Acquisition, Development Milestone Payment Asset Acquisition, Development Milestone Payment Number of equal quarterly installments Share Based Compensation Arrangement By Share Based Payment Award Periodic Vesting Number Of Installments Share-based compensation arrangement by share-based payment award, periodic vesting, number of installments. Purchase commitment, option for non-auto renewal, prior written notice period (in months) Purchase Commitment, Option For Non-Auto Renewal, Prior Written Notice Period Purchase Commitment, Option For Non-Auto Renewal, Prior Written Notice Period Payments due to Q32 Bio Inc. Accrued Milestone Payments Due, Current Accrued Milestone Payments Due, Current Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Public Stock Offering - Underwriting Agreement Public Stock Offering - Underwriting Agreement [Member] Public Stock Offering - Underwriting Agreement Liability related to sale of future royalties, net of current portion Long-term portion Contractual Arrangement, Royalties Agreement, Liability, Noncurrent Contractual Arrangement, Royalties Agreement, Liability, Noncurrent Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Maximum employee subscription amount Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Employee Subscription Amount Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Employee Subscription Amount Total settlement royalties liability Contractual Arrangement, Royalties Agreement, Settlement Liability Contractual Arrangement, Royalties Agreement, Settlement Liability Operating lease liabilities Operating Lease, Liability, Current Schedule of Allowance for Credit Losses Accounts Receivable, Allowance for Credit Loss [Table Text Block] NET INCOME (LOSS) PER SHARE Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Earnings Per Share [Abstract] Non-cash interest expense Noncash Interest Expense Noncash interest expense. Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Contract asset: Contract With Customer, Asset, After Allowance For Credit Loss, Current [Roll Forward] Contract With Customer, Asset, After Allowance For Credit Loss, Current Royalty payments Royalty Payment Royalty Payment Auryxia Drug Substance Auryxia Drug Substance [Member] Auryxia Drug Substance Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Schedule of Product Revenues Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Table Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Geographical Geographical [Domain] Purchases of equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Unrecognized compensation costs, options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date [Member] Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date Company Selected Measure Name Company Selected Measure Name Sale of Stock Sale of Stock [Domain] Purchase Commitment, Excluding Long-term Commitment Purchase Commitment, Excluding Long-Term Commitment [Axis] Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Restricted Stock Units (RSUs) And Performance Based Restricted Stock Units (PSUs) Restricted Stock Units (RSUs) And Performance Based Restricted Stock Units (PSUs) [Member] Restricted Stock Units (RSUs) And Performance Based Restricted Stock Units (PSUs) Tiered royalty payments, percentage Tiered Royalty Payments, Percentage Tiered Royalty Payments, Percentage Product revenue allowances excluding rebates Accrued Product Revenue Allowances Excluding Rebates, Current Accrued product revenue allowances current. Warrant purchased (in shares) Class of Warrant or Right, Warrants Purchased Class of Warrant or Right, Warrants Purchased Excess firm purchase commitment charge Long-Term Purchase Commitment, Amount Total before unamortized discount and issuance costs Long-Term Debt, Gross Operating lease, increase in rent, percentage Lessee, Operating Lease, Increase In Rent, Percentage Lessee, Operating Lease, Increase In Rent, Percentage License License Expense License expense. Credit Facility Credit Facility [Domain] Operating Activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Dilutive effect of warrants Warrants Warrant [Member] Diluted (in shares) Denominator for diluted net income (loss) per share - weighted average outstanding shares of common stock and assumed conversions (in shares) Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Schedule of Prepaid Expenses and Other Current Assets Schedule of Other Current Assets [Table Text Block] Line of Credit Facility [Table] Line of Credit Facility [Table] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Less: present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Other long-term assets Increase (Decrease) in Other Noncurrent Assets Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] HealthCare Royalty Partners IV, L.P. HealthCare Royalty Partners IV, L.P. [Member] HealthCare Royalty Partners IV, L.P. Additions Contract With Customer Asset Additions Contract with customer asset additions. Direct cost of product and other revenue Product and Other Revenue Expense Product and Other Revenue Expense Impairment of fixed assets Long-Lived Asset, Held and Used, Impairment Loss Operating lease, payments Operating Lease, Payments Right-of-use asset and lease liability Payments To Transfer Rights And Obligations Of Operating Lease Payments To Transfer Rights And Obligations Of Operating Lease Cost of goods sold Cost of Revenue [Abstract] Award Timing Predetermined Award Timing Predetermined [Flag] Restricted cash Restricted Cash, Current Intangible Asset, Goodwill and Other [Abstract] Intangible Asset, Goodwill and Other [Abstract] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] JT and Torii Japan Tobacco Incorporation And Torii Pharmaceutical Company Limited [Member] Japan tobacco incorporation and torii pharmaceutical company limited. Total lease commitments Lessee, Operating Lease, Liability, to be Paid Area of property leased (in square feet) Area of Real Estate Property Exit fee percentage Debt Instrument, Exit Fee Percentage Debt Instrument, Exit Fee Percentage Development And Commercialize Collaboration Agreement Development And Commercialize Collaboration Agreement [Member] Development and commercialize collaboration agreement Fair value at grant date (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Fair Value At Grant Date Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Fair Value At Grant Date Transaction fee percentage Debt Instrument, Transaction Fee Percentage Debt Instrument, Transaction Fee Percentage Dilutive effect (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Outstanding beginning balance, weighted average grant date fair value (in dollars per share) Outstanding ending balance, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Inventory, Current [Table] Inventory, Current [Table] All Executive Categories All Executive Categories [Member] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Working Capital Fund liability, net of current portion Long-term portion Contract with Customer, Refund Liability, Noncurrent Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share LIABILITY RELATED TO SETTLEMENT ROYALTIES, WORKING CAPITAL FUND LIABILITY AND LIABILITY RELATED TO SALE OF FUTURE ROYALTIES Other Liabilities Disclosure [Text Block] Depreciation Depreciation Vesting Vesting [Domain] Plan Name Plan Name [Domain] Antidilutive Securities Antidilutive Securities [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Maximum annual royalty payout capacity Contractual Arrangement, Royalties Agreement, Maximum Annual Royalty Payout Capacity Contractual Arrangement, Royalties Agreement, Maximum Annual Royalty Payout Capacity Scenario Scenario [Domain] Outstanding beginning balance (in dollars per share) Outstanding ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Earnings per share: Earnings Per Share, Basic and Diluted EPS [Abstract] Earnings Per Share, Basic and Diluted EPS Operating right-of-use assets Operating Lease, Right-of-Use Asset STOCK-BASED COMPENSATION PLANS Shareholders' Equity and Share-Based Payments [Text Block] Lease extension period Lessee, Operating Lease, Renewal Term Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Royalty payments License Collaboration And Other Revenue, Royalties [Member] License Collaboration And Other Revenue, Royalties Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument, Name Debt Instrument, Name [Domain] SEGMENT INFORMATION Segment Reporting [Text Block] Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Sublicense Agreement Sublicense Agreement [Member] Sublicense agreement. Denominator Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Income Statement Location Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Options outstanding, weighted-average remaining contractual life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Options exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Proceeds from common stock sold Proceeds from Issuance of Common Stock Common stock, authorized (in shares) Common stock, authorized (in shares) Common Stock, Shares Authorized Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Number of shares sold in offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Repayment of liability related to settlement royalties Repayment Of Liability Related To Settlement Royalties Repayment Of Liability Related To Settlement Royalties Exercise Price Award Exercise Price Investing Activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Segment Reporting [Line Items] Segment Reporting [Line Items] Unrecognized compensation costs, stock Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Milestone revenue Milestone Payment Received Milestone payment received. Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Sales to AG Distributor Sales to AG Distributor [Member] Sales to AG Distributor Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss INDEBTEDNESS Debt Disclosure [Text Block] Scenario Scenario [Axis] Issuance of warrants in connection with BlackRock Credit Agreement Non-Cash Financing Activities, Issuance of Warrants Non-Cash Financing Activities, Issuance of Warrants Less: unamortized discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Accrued manufacturing costs Accrued Manufacturing Costs, Current Accrued Manufacturing Costs, Current Equity Component Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Secured Debt Secured Debt [Member] Total Working Capital Fund liability Contract with Customer, Refund Liability Product rebates Accrued Product Rebates, Current Accrued Product Rebates, Current Aggregate net proceeds from offering Sale of Stock, Consideration Received on Transaction Adoption Date Trading Arrangement Adoption Date Counterparty Name Counterparty Name [Domain] Debt instrument, interest rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Assets Assets [Abstract] Contract liability: Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Other Liabilities Disclosure [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Current operating lease liabilities Operating Lease, Liability Insider Trading Policies and Procedures [Line Items] Number of options outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number ADDITIONAL BALANCE SHEET DETAIL Accounts Payable and Accrued Liabilities Disclosure [Text Block] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expense Private Placement Private Placement [Member] Repayment of term debt Repayments of Debt Office And Storage Space Office And Storage Space [Member] Office And Storage Space Interest expense Interest Income (Expense), Nonoperating Total security deposit in connection with lease Security Deposit Letter of Credit Letter of Credit [Member] Development And Commercialize Research And License Agreement Development And Commercialize Research And License Agreement [Member] Development and commercialize research and license agreement. COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] STA Pharmaceutical Hong Kong Limited STA Pharmaceutical Hong Kong Limited [Member] STA Pharmaceutical Hong Kong Limited Late fee percentage Debt Instrument, Late Fee Percentage Debt Instrument, Late Fee Percentage Number of operating segments Number of Operating Segments Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Unvested RSUs Dilutive effect of RSUs Restricted Stock Units (RSUs) [Member] Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Proceeds from customers Proceeds from Customers Entity Central Index Key Entity Central Index Key Additional paid-in capital Additional Paid in Capital, Common Stock All Adjustments to Compensation All Adjustments to Compensation [Member] Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash provided by (used in) operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Regulatory Milestone Payments Regulatory Milestone Payments [Member] Regulatory milestone payments. Rebates, Fees and Other Deductions Rebates Fees And Other Deductions [Member] Rebates, Fees and other Deductions. 2026 Long-Term Debt, Maturity, Remainder of Fiscal Year Annual interest rate, increase (as percent) Debt Instrument, Annual Interest Rate, Increase (Decrease) Debt Instrument, Annual Interest Rate, Increase (Decrease) Income Statement [Abstract] Income Statement [Abstract] Stockholders' equity: Equity, Attributable to Parent [Abstract] Proceeds from sale of stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Document Transition Report Document Transition Report Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Additional payment term Asset Acquisition, Additional Payment Term Asset Acquisition, Additional Payment Term Operating expenses: Operating Expenses [Abstract] Share-Based Payment Arrangement, Tranche Two, Following First Anniversary After Grant Date Share-Based Payment Arrangement, Tranche Two, Following First Anniversary After Grant Date [Member] Share-Based Payment Arrangement, Tranche Two, Following First Anniversary After Grant Date Refund liability to customer, amortization of discount Contract with Customer, Refund Liability, Amortization of Discount Contract with Customer, Refund Liability, Amortization of Discount SARs Stock Appreciation Rights (SARs) [Member] Adjustments related to prior year sales Valuation Allowances And Reserves Adjustments Related To Prior Period Sales Valuation allowances and reserves adjustments related to prior period sales. Vifor (International) Ltd. Vifor International Limited [Member] Vifor International Limited. Schedule of Assumptions Used in Black-Scholes Option Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Total security deposit in connection with lease Lessee, Operating Lease, Security Deposit Lessee, Operating Lease, Security Deposit Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Basis spread on variable rate (as percent) Debt Instrument, Basis Spread on Variable Rate City Area Code City Area Code Panion & BF Biotech, Inc Panion & BF Biotech, Inc [Member] Panion & BF Biotech, Inc Working Capital Fund liability, current portion Current portion Contract with Customer, Refund Liability, Current All Individuals All Individuals [Member] SUBSEQUENT EVENTS Subsequent Events [Text Block] Bad debt expense Accounts Receivable, Credit Loss Expense Accounts Receivable, Credit Loss Expense Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Variable rate, floor (as percent) Debt Instrument, Variable Rate Floor Debt Instrument, Variable Rate Floor Expiration period beginning with first commercial sale (in years) Expiration Period Beginning with First Commercial Sale Expiration Period Beginning with First Commercial Sale Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Name Forgone Recovery, Individual Name Supply agreement Supply Agreement [Member] Supply Agreement Finished goods Inventory, Finished Goods, Net of Reserves Unrecognized compensation costs, options, period for recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Proceeds from issuance of common stock, net of issuance costs Proceeds From Issuance Of Common Stock Net Of Issuance Costs Proceeds from issuance of common stock net of issuance costs. Statement [Line Items] Statement [Line Items] Total assets Assets Operating Lease Commitments Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Common stock, reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance CSL Vifor CSL Vifor [Member] CSL Vifor Schedule of Stock-Based Compensation Expense in Consolidated Statement of Operations and Comprehensive Loss Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Deductions Deductions Contract With Customer Liability Deductions Contract with customer liability deductions. Inducement Award Program Inducement Award Program [Member] Inducement award program. Proceeds from sale of stock under    employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan NATURE OF BUSINESS Nature of Operations [Text Block] Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues PEO PEO [Member] 2028 Long-Term Debt, Maturity, Year Two Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Stock-based compensation expense Total stock-based compensation Share-Based Payment Arrangement, Expense Sale of stock, consideration received, gross Sale of Stock, Consideration Received on Transaction, Gross Sale of Stock, Consideration Received on Transaction, Gross Other long-term liabilities Other Liabilities, Noncurrent Goodwill Goodwill Warrants issued (in shares) Class of Warrant or Right, Warrants Issued Class of Warrant or Right, Warrants Issued Commercial milestone payment Asset Acquisition, Consideration Transferred, Contingent Consideration, Commercial Milestone Payment "Asset Acquisition, Consideration Transferred, Contingent Consideration, Commercial Milestone Payment Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Auryxia Auryxia [Member] Auryxia Exercise of options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Granted, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Number of performance obligations Number Of Performance Obligations Number of performance obligations. Deferred revenue — beginning of the period Revenue recognized Contract with Customer, Liability, Revenue Recognized Payables and Accruals [Abstract] Payables and Accruals [Abstract] Accumulated Deficit Retained Earnings [Member] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Total operating expenses Operating Expenses Forfeited and canceled, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Current provisions related to sales in current year SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Accumulated Other Comprehensive Income AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Canceled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Payments of issuance costs related to BlackRock Credit Agreement Payments of Debt Issuance Costs Diluted (in dollars per share) Diluted net income (loss) per share (in dollars per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Total Shareholder Return Amount Total Shareholder Return Amount Issuance and sale of equity securities Issuance And Sale Of Equity Securities, Amount Issuance And Sale Of Equity Securities, Amount Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service [Member] Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service Lessee, operating lease, expiration period (in months) Lessee, Operating Lease, Expiration Period Lessee, Operating Lease, Expiration Period Inventory [Domain] Inventory [Domain] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Capital stock, authorized (in shares) Capital Stock, Shares Authorized Capital Stock, Shares Authorized Proceeds from line of credit Proceeds from Long-Term Lines of Credit Schedule of Product Revenue Allowance and Provision Categories Schedule Of Product Revenue Allowance And Reserve Categories [Table Text Block] Schedule Of Product Revenue Allowance And Reserve Categories. Research and development Research and Development Expense Adjustments to reconcile net income (loss) to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Financing Activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Total revenues Recognized revenue Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Prepayment fee percentage Debt Instrument, Prepayment Fee Percentage Debt Instrument, Prepayment Fee Percentage Maximum aggregate royalty payout capacity Contractual Arrangement, Royalties Agreement, Maximum Aggregate Royalty Payout Capacity Contractual Arrangement, Royalties Agreement, Maximum Aggregate Royalty Payout Capacity INVENTORIES Inventory Disclosure [Text Block] Exercise of options Stock Issued During Period, Value, Stock Options Exercised Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] GOODWILL Intangible Asset and Goodwill [Text Block] Underlying Securities Award Underlying Securities Amount Debt covenant, revenue Debt Instrument, Covenant, Revenue Debt Instrument, Covenant, Revenue PRODUCT REVENUE AND PROVISIONS FOR VARIABLE CONSIDERATION Revenue from Contract with Customer [Text Block] Issuance of common stock, net of    issuance costs Stock Issued During Period, Value, New Issues Net income (loss) per share: Earnings Per Share, Basic And Diluted1 [Abstract] Earnings Per Share, Basic And Diluted1 Over-Allotment Option Over-Allotment Option [Member] Term Loan Facility, Tranche A Term Loan Facility, Tranche A [Member] Term Loan Facility, Tranche A Total inventories Inventory Net Current And Non Current Inventory net current and non current. Canceled and forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Medice MEDICE Arzneimittel Pütter GmbH & Co. KG MEDICE Arzneimittel Pütter GmbH & Co. KG [Member] MEDICE Arzneimittel Pütter GmbH & Co. KG Liability related to sale of future royalties, current portion Current portion (included in accrued expenses and other current liabilities) Contractual Arrangement, Royalties Agreement, Liability, Current Contractual Arrangement, Royalties Agreement, Liability, Current Inventory Increase (Decrease) in Inventories Operating lease, borrowing rate Operating Lease, Weighted Average Discount Rate, Percent Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Segment Reporting [Table] Segment Reporting [Table] Additional awards available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Awards outstanding (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Outstanding, Number Share-Based Compensation Arrangement By Share-Based Payment Award, Outstanding, Number Maximum employee subscription rate (as percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Schedule of Future Principal Payments on the Term Loans Schedule of Maturities of Long-Term Debt [Table Text Block] Outstanding common stock options Share-Based Payment Arrangement, Option And Stock Appreciation Rights [Member] Share-Based Payment Arrangement, Option And Stock Appreciation Rights Title of Individual Title and Position [Axis] Sale of Stock Sale of Stock [Axis] Weighted-Average Contractual Life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Other Other Assets, Current Schedule of Revenue Recognized Resulting from Changes in Contract Assets and Contract Liabilities Schedule Of Revenue Recognized Resulting From Changes In Contract Asset And Contract Liability [Table Text Block] Schedule of revenue recognized resulting from changes in contract asset and contract liability. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Income (loss) from operations Operating Income (Loss) Transaction price Revenue, Remaining Performance Obligation, Amount Current Fiscal Year End Date Current Fiscal Year End Date 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Proceeds from the issuance of debt Proceeds from Issuance of Debt Royalty true-up payments Royalty True-Up Payments Royalty True-Up Payments Purchase of IPR&D asset included in accrued expenses and other current liabilities In Process Research And Development Asset Expenditure Incurred But Not Yet Paid In Process Research And Development Asset Expenditure Incurred But Not Yet Paid Clinical trial costs Accrued Clinical Expenses Current Accrued clinical expenses current. Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Operating lease extensions (in extension options) Lessee, Operating Lease, Renewal Options Lessee, Operating Lease, Renewal Options Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Purchase commitment, option to extend, prior notice period (in months) Long-Term Purchase Commitment, Option To Extend, Prior Notice Period Long-Term Purchase Commitment, Option To Extend, Prior Notice Period Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service [Member] Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Amended Supply Agreement Amended Supply Agreement [Member] Amended Supply Agreement Additional upfront payment Asset Acquisition, Additional Upfront Payment Asset Acquisition, Additional Upfront Payment Common stock, issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Contract with Customer, Basis of Pricing Contract with Customer, Basis of Pricing [Axis] Refund liability to customer, amortization of deferred gain Contract with Customer, Refund Liability, Amortization of Deferred Gain Contract with Customer, Refund Liability, Amortization of Deferred Gain Royalties due to Panion & BF Biotech, Inc. Accrued Royalties, Current Tiered royalty payments as a percentage of net sales Tiered Royalty Payments as a Percentage of Net Sales Tiered Royalty Payments as a Percentage of Net Sales Cost of product and other revenue Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Equity Components Equity Components [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Product and Service Product and Service [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Restructuring costs Restructuring Reserve, Current Entity Interactive Data Current Entity Interactive Data Current Liability related to settlement royalties, net of current portion Long-term portion Contractual Arrangement, Royalties Agreement, Settlement Liability, Noncurrent Contractual Arrangement, Royalties Agreement, Settlement Liability, Noncurrent Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Termination Date Trading Arrangement Termination Date Subsequent Events [Abstract] Chargebacks and Discounts Chargebacks And Discounts [Member] Chargebacks and Discounts. Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Expiration period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other long-term assets Total other long-term assets Other Assets, Noncurrent Document Type Document Type Share-based Compensation Award, Tranche, First Anniversary of Grant Date Share Based Compensation Award Tranche First Anniversary Of Grant Date [Member] Share-based compensation award, tranche, first anniversary of grant date. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities, Current Unregistered stock held by customer (in shares) Contract With Customer, Number Of Unregistered Stock Held By Customer Contract With Customer, Number Of Unregistered Stock Held By Customer Purchase Commitment, Excluding Long-term Commitment Purchase Commitment, Excluding Long-Term Commitment [Domain] Fair Value as of Grant Date Award Grant Date Fair Value SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Settlement royalties liability, current portion Current portion (included in accrued expenses and other current liabilities) Contractual Arrangement, Royalties Agreement, Settlement Liability, Current Contractual Arrangement, Royalties Agreement, Settlement Liability, Current Long-term purchase commitment, option to terminate, prior notice period (at least) Long-Term Purchase Commitment, Option To Terminate, Prior Notice Period Long-Term Purchase Commitment, Option To Terminate, Prior Notice Period Charge for purchase of IPR&D asset Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Number of financial institutions maintaining cash Cash, Number Of Financial Institutions Held Within Cash, Number Of Financial Institutions Held Within Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Upfront cash payment received Upfront Cash Payment Received Upfront cash payment received. Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Long-term deferred revenue Contract with Customer, Liability, Noncurrent Repayment of WCF liability Repayment Of Working Capital Fund Liability Repayment Of Working Capital Fund Liability Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Akebia Therapeutics, Inc. 2023 Stock Incentive Plan (the 2023 Plan) (replaces 2014 Plan) Akebia Therapeutics, Inc. 2023 Stock Incentive Plan (the 2023 Plan) (replaces 2014 Plan), as amended 2023 Plan Stock Incentive Plan, 2023 [Member] Stock Incentive Plan, 2023 Warrant exercise period (in years) Warrants and Rights Outstanding, Term Commitments and contingencies (Note 10) Commitments and Contingencies Schedule of Liability Related to Sale of Future Royalties Other Noncurrent Liabilities [Table Text Block] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Number of commercial products Number Of Commercial Products Number Of Commercial Products Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Three Lessee, Operating Lease, Liability, to be Paid, after Year Three Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Refund liability to customer, interest rate (as percent) Contract with Customer, Refund Liability, Interest Rate Contract with Customer, Refund Liability, Interest Rate Executive Category: Executive Category [Axis] Schedule of RSU and PSU Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Keryx Equity Plans Keryx Equity Plans [Member] Keryx Equity Plans Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Counterparty Name Counterparty Name [Axis] Liabilities and stockholders' equity Liabilities and Equity [Abstract] Options exercisable at end of period, weighted-average remaining contractual life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term Purchase of IPR&D asset Payments to Acquire in Process Research and Development Inventories Inventories, current Inventory, Net Award Type Award Type [Domain] Vifor International Limited, First Investment Vifor International Limited, First Investment [Member] Vifor International Limited, First Investment Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount 2026 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Product Returns Returns [Member] Returns. Level 3 Fair Value, Inputs, Level 3 [Member] Q32 Q32 [Member] Q32 Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term PEO Name PEO Name Geographical Geographical [Axis] Accrued expense and other current liabilities Increase (Decrease) in Accrued Liabilities Restricted cash Restricted Cash Deferred revenue Balance at Beginning of Period Balance at End of Period Contract with Customer, Liability Long-Lived Asset, Class Long-Lived Asset, Class [Axis] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Offering period (in months) Share Based Compensation Arrangement By Share Based Payment Award Offering Period Share-based compensation arrangement by share-based payment award, offering period. Entity Tax Identification Number Entity Tax Identification Number Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Interest expense Interest Expense, Debt Credits/payments made SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Cost of purchased minimum quantity product Cost Of Purchased Minimum Quantity Product Cost of purchased minimum quantity product. Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash, cash equivalents and restricted cash — beginning of period Cash, cash equivalents and restricted cash — end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Lessee, operating lease, cost of additional square foot (in dollars per sq foot) Lessee, Operating Lease, Cost Of Additional Square Foot Lessee, Operating Lease, Cost Of Additional Square Foot Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Professional fees Accrued Professional Fees, Current Accounts payable Increase (Decrease) in Accounts Payable Other Other Accrued Liabilities, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Debt instrument, cap rate (as percent) Debt Instrument, Interest Rate Cap Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Akebia Therapeutics, Inc. 2014 Incentive Plan, as amended (the 2014 Plan) 2014 Plan Incentive Plan, 2014 [Member] Incentive Plan, 2014 Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument Debt Instrument [Axis] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Purchase price at the end of offering period Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Dilutive effect of ESPP Employee Stock [Member] Contingent consideration Asset Acquisition, Consideration Transferred, Contingent Consideration Leased area subject to expiration Lessee, Operating Lease, Area Subject To Expiration Lessee, Operating Lease, Area Subject To Expiration Schedule of Components Inventory Schedule of Inventory, Current [Table Text Block] LEASES Lessee, Operating Leases [Text Block] 2027 Long-Term Debt, Maturity, Year One Long-Term Debt, Type Long-Term Debt, Type [Domain] Basic (in dollars per share) Basic net income (loss) per share (in dollars per share) Earnings Per Share, Basic Cyclerion Amendment Cyclerion Amendment [Member] Cyclerion Amendment Laboratory Space Laboratory Space [Member] Laboratory Space Schedule of Equity Incentive Plans Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Current portion of deferred revenue Contract with Customer, Liability, Current Total current assets Assets, Current Statistical Measurement Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Long-term debt, net of current portion Long-Term Debt, Excluding Current Maturities Total cost of goods sold Cost of Revenue Award Type Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Specified development and regulatory milestone payments, contingent on a product-by-product basis Asset Acquisition, Consideration Transferred, Contingent Consideration, Development and Regulatory Milestone Payments Asset Acquisition, Consideration Transferred, Contingent Consideration, Development and Regulatory Milestone Payments Accumulated deficit Retained Earnings (Accumulated Deficit) Product return provisions, current portion Accrued Product Revenue Return Reserves, Current Accrued Product Revenue Return Reserves, Current Product and Service Product and Service [Axis] License, collaboration and other revenue License, Collaboration And Other Revenue [Member] License, collaboration and other revenue. Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Schedule of Revenues Recognized from License, Collaboration and Other Significant Agreements Collaborative Arrangement Revenue Recognition [Table Text Block] Collaborative arrangement revenue recognition. Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Operating lease, cost Operating Lease, Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Number of shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Cover [Abstract] Cover [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate WuXi STA WuXi STA [Member] WuXi STA Unrecorded unconditional purchase obligation Unrecorded Unconditional Purchase Obligation, to be Paid, Year One Supply Agreement, Patheon Inc. Supply Agreement, Patheon Inc. [Member] Supply Agreement, Patheon Inc. Equity Awards Adjustments Equity Awards Adjustments [Member] Eligible milestone payments (up to) Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Total liability related to sale of future royalties Contractual Arrangement, Royalties Agreement, Liability Contractual Arrangement, Royalties Agreement, Liability LICENSE, COLLABORATION AND OTHER REVENUE Collaborative Arrangement Disclosure [Text Block] Total liabilities and stockholders' equity Liabilities and Equity Warrant liability Derivative Liability, Noncurrent Share-based Payment Arrangement, Option Share-Based Payment Arrangement, Option [Member] Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Plan Name Plan Name [Axis] Restructuring Restructuring Charges Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Tabular List, Table Tabular List [Table Text Block] Vesting Vesting [Axis] Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Other income (expense) Other Nonoperating Income (Expense) Mitsubishi Tanabe Pharma Corporation Supply Agreement Mitsubishi Tanabe Pharma Corporation Supply Agreement [Member] Mitsubishi Tanabe Pharma Corporation Supply Agreement Weighted average shares of common stock outstanding: Weighted Average Number Of Shares Outstanding, Basic And Diluted [Abstract] Weighted Average Number Of Shares Outstanding, Basic And Diluted Name Awards Close in Time to MNPI Disclosures, Individual Name Tiered royalties, expected timing of satisfaction period (in years) Revenue, Remaining Performance Obligation, Variable Consideration, Royalty, Expected Timing Of Satisfaction, Period Revenue, Remaining Performance Obligation, Variable Consideration, Royalty, Expected Timing Of Satisfaction, Period Office Space Office Space [Member] Office space . Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Options outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Forfeited and canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Long-Lived Asset, Class Long-Lived Asset, Class [Domain] Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Preferred stock $0.00001 par value; 25,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025 Preferred Stock, Value, Issued Term Loan Facility, Tranche C Term Loan Facility, Tranche C [Member] Term Loan Facility, Tranche C Adjustment to Compensation: Adjustment to Compensation [Axis] Deductions Contract With Customer Asset Deductions Contract with customer asset deductions. Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Inventory [Line Items] Inventory [Line Items] Credit Facility Credit Facility [Axis] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Debt covenant, revenue period (in months) Debt Instrument, Covenant, Revenue, Period Debt Instrument, Covenant, Revenue, Period Name Measure Name Accounts payable Payables Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Term Loan Facility Term Loan Facility [Member] Term Loan Facility Contract cost incurred in research and development activities Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-In Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Termination of agreement by counterparty, written notice period (in months) Contract With Customer, Termination Notice Period Contract With Customer, Termination Notice Period Director Director [Member] Debt covenant, cash and cash equivalents Debt Instrument, Covenant, Cash And Cash Equivalents Debt Instrument, Covenant, Cash And Cash Equivalents Name Trading Arrangement, Individual Name At-The-Market Sale Agreement, Authorized April 2022, Amended At-The-Market Sale Agreement, Authorized April 2022, Amended [Member] At-The-Market Sale Agreement, Authorized April 2022, Amended Cash and cash equivalents Cash and Cash Equivalent Siegfried Evionnaz SA Siegfried Evionnaz S A [Member] Siegfried Evionnaz SA. Raw materials Inventory, Raw Materials, Net of Reserves SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Company Selected Measure Amount Company Selected Measure Amount Vafseo Vafseo [Member] Vafseo Cost of research services Cost Of Research Services Cost of research services. License Collaboration And Other Revenue [Abstract] License Collaboration And Other Revenue [Abstract] License, collaboration and other revenue. Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Current assets: Assets, Current [Abstract] Operating lease term Operating Lease, Weighted Average Remaining Lease Term Warrant liability Derivative Liability Non-PEO NEO Non-PEO NEO [Member] Vifor International Limited, Second Investment Vifor International Limited, Second Investment [Member] Vifor International Limited, Second Investment Entity Address, Address Line One Entity Address, Address Line One Right-of-use asset obtained in exchange for lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Vested, weighted-average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Income tax expense Income Tax Expense (Benefit) Effect of potential dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] License Agreement License Agreement [Member] License agreement. SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Q32 Asset Purchase Agreement Q32 Asset Purchase Agreement [Member] Q32 Asset Purchase Agreement Award Timing Method Award Timing Method [Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Percentage of royalty payment to be received once maximum annual royalty payout has been paid Contractual Arrangement, Royalties Agreement, Percentage Contractual Arrangement, Royalties Agreement, Percentage Forecast Forecast [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Cambridge Cambridge [Member] Cambridge. Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum TPC Tanabe Pharma Corporation Tanabe Pharma Corporation [Member] Mitsubishi Tanabe Pharma Corporation. Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Long-Term Debt, Type Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Balance Sheet Location Location, Statement of Financial Position, Balance [Axis] Proceeds from the sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Statement [Table] Statement [Table] Share Based Compensation Award Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Annual effective interest rate (as percent) Contractual Arrangement, Royalties Agreement, Interest Rate, Effective Percentage Contractual Arrangement, Royalties Agreement, Interest Rate, Effective Percentage Restatement Determination Date: Restatement Determination Date [Axis] Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Public Stock Offering Public Stock Offering [Member] Public Stock Offering Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Reportable Segment Reportable Segment [Member] Reportable Segment Options exercisable at end of period, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule of Changes in Contract Assets and Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Acquired Licenses Acquired Licenses [Member] Acquired Licenses Revenue Recognized in the Period: Change in Contract with Customer, Liability [Abstract] Asset acquisition, consideration transferred, transaction cost Asset Acquisition, Consideration Transferred, Transaction Cost Revenues Revenues [Abstract] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Secured Overnight Financing Rate (SOFR) [Member]